These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15761997)

  • 21. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
    Ghali JK; Tam SW; Ferdinand KC; Lindenfeld J; Sabolinski ML; Taylor AL; Worcel M; Curry CL; Cohn JN;
    Am J Cardiovasc Drugs; 2007; 7(5):373-80. PubMed ID: 18041162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Food & Drug Administration panel approves heart failure medication aimed at African-Americans.
    Pharmacogenomics; 2005 Jul; 6(5):455. PubMed ID: 16705760
    [No Abstract]   [Full Text] [Related]  

  • 23. Dilemmas With Race and Heart Failure Treatment.
    Butler J; Konstam MA
    Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27707751
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
    Cohn JN; Archibald DG; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Francis GS; Flohr KH
    N Engl J Med; 1986 Jun; 314(24):1547-52. PubMed ID: 3520315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gray area for new heart failure drug. Although the FDA approved BiDil for blacks with heart failure, it may work in anyone.
    Harv Heart Lett; 2005 Nov; 16(3):1-2. PubMed ID: 16363036
    [No Abstract]   [Full Text] [Related]  

  • 26. Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
    Thadani U; Jacob RG
    Drugs Today (Barc); 2008 Dec; 44(12):925-37. PubMed ID: 19198701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure.
    Wilson RM; De Silva DS; Sato K; Izumiya Y; Sam F
    Hypertension; 2009 Sep; 54(3):583-90. PubMed ID: 19620510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure.
    Echols MR; Yancy CW
    Vasc Health Risk Manag; 2006; 2(4):423-31. PubMed ID: 17323596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Underuse of hydralazine and isosorbide dinitrate for heart failure in patients of African ancestry: a cross-European survey.
    Brewster LM
    ESC Heart Fail; 2019 Jun; 6(3):487-498. PubMed ID: 30892835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Popular representations of race: the news coverage of BiDil.
    Caulfield T; Harry S
    J Law Med Ethics; 2008; 36(3):485-90. PubMed ID: 18840240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BiDil for heart failure in black patients.
    Kahn JD
    Ann Intern Med; 2007 Aug; 147(3):215; author reply 215-6. PubMed ID: 17679713
    [No Abstract]   [Full Text] [Related]  

  • 32. BiDil for heart failure in black patients.
    Bibbins-Domingo K; Fernandez A
    Ann Intern Med; 2007 Aug; 147(3):214-5; author reply 215-6. PubMed ID: 17679712
    [No Abstract]   [Full Text] [Related]  

  • 33. BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.
    Carmody MS; Anderson JR
    Cardiol Rev; 2007; 15(1):46-53. PubMed ID: 17172884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure.
    Hammermeister KE; Fairclough D; Emsermann CB; Hamman R; Ho M; Phibbs S; Plomondon M; Valuck R; West D; Steiner JF
    Clin Ther; 2009 Mar; 31(3):632-43. PubMed ID: 19393854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there a drug of choice for vasodilator therapy in patients with refractory heart failure?
    Packer M
    Chest; 1980 Jan; 77(1):7-9. PubMed ID: 7351152
    [No Abstract]   [Full Text] [Related]  

  • 36. Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?
    Ferdinand KC
    J Law Med Ethics; 2008; 36(3):458-63. PubMed ID: 18840236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.
    Temple R; Stockbridge NL
    Ann Intern Med; 2007 Jan; 146(1):57-62. PubMed ID: 17200223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction.
    Golwala HB; Thadani U; Liang L; Stavrakis S; Butler J; Yancy CW; Bhatt DL; Hernandez AF; Fonarow GC
    J Am Heart Assoc; 2013 Aug; 2(4):e000214. PubMed ID: 23966379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
    Cohn JN; Johnson G; Ziesche S; Cobb F; Francis G; Tristani F; Smith R; Dunkman WB; Loeb H; Wong M
    N Engl J Med; 1991 Aug; 325(5):303-10. PubMed ID: 2057035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.
    Colvin-Adams M; Taylor AL
    Cleve Clin J Med; 2007 Mar; 74(3):227-34. PubMed ID: 17375804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.